Tracers / [177Lu]Lu-DOTA-EB-TATE
[177Lu]Lu-DOTA-EB-TATE
Also written as [Lu-177]Lu-DOTA-EB-TATE; Lu-177-DOTA-EB-TATE
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- Somatostatin analogue (radiolabelled peptide, DOTA-conjugated, Evans blue-modified for albumin binding)
- Target / mechanism
- Somatostatin receptor binding, with Evans blue moiety for albumin binding to prolong blood residence time PMID 33452632
- Clinical application
- Peptide receptor radionuclide therapy in patients with somatostatin receptor-positive progressive disease PMID 33452632
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >97% | — | DOTA-EB-TATE | 33452632 2021 Eur J Nucl Med Mol Imaging The radiosynthesis of [177Lu]Lu-DOTA-EB-TATE was carried out in our GMP laboratory with the same operating procedure that is commonly used for dosimetric activities of [177Lu]Lu-DOTA-TOC — the radiochemical yield was > 97% in all cases |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-EB-TATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.